The American Pharmacists Association (APhA) has launched new and current training programs and resources to assist responders on the front lines of health care in staying safe and up to date with the latest research and practice guidance for the COVID-19 pandemic, it was reported on Tuesday.
APhA vice president, Professional Education Resources, Daniel Zlott, PharmD, BCOP, said, 'We are diligently working on behalf of pharmacists and patients to address the training needs of all as we face unprecedented times. Pharmacists can assist patients in a number of ways, including helping to increase the number of individuals who are able to be tested for COVID-19 and providing education to patients.'
The APhA's COVID-19 Specimen Collection Training guides pharmacists through the collection of nasopharyngeal swabs. The program will be adaptable to other testing methods once they become more widely available, such as nasal swabs, oral swabs, fingerstick tests, and other new technologies.
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Lupin launches Dasatinib tablets in US market
WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Ascletis Pharma Inc reports topline results from Phase III open-label study of denifanstat
Innovative Molecules GmbH completes Phase 1 clinical development programme for adibelivir
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA